These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31104228)

  • 21. Elucidation of Factor VIII Activity Pharmacokinetics: A Pooled Population Analysis in Patients With Hemophilia A Treated With Moroctocog Alfa.
    Abrantes JA; Nielsen EI; Korth-Bradley J; Harnisch L; Jönsson S
    Clin Pharmacol Ther; 2017 Dec; 102(6):977-988. PubMed ID: 28437834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical application of Web Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Patterns of blood sampling and patient characteristics among clinician users.
    McEneny-King A; Yeung CH; Edginton AN; Iorio A; Croteau SE
    Haemophilia; 2020 Jan; 26(1):56-63. PubMed ID: 31742831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Common Genetic Variants in ABO and CLEC4M Modulate the Pharmacokinetics of Recombinant FVIII in Severe Hemophilia A Patients.
    Garcia-Martínez I; Borràs N; Martorell M; Parra R; Altisent C; Ramírez L; Álvarez-Román MT; Nuñez R; Megias-Vericat JE; Corrales I; Alonso S; Vidal F
    Thromb Haemost; 2020 Oct; 120(10):1395-1406. PubMed ID: 32726853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Handling interoccasion variability in model-based dose individualization using therapeutic drug monitoring data.
    Abrantes JA; Jönsson S; Karlsson MO; Nielsen EI
    Br J Clin Pharmacol; 2019 Jun; 85(6):1326-1336. PubMed ID: 30767254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The "OPTI-CLOT" trial. A randomised controlled trial on periOperative PharmacokineTIc-guided dosing of CLOTting factor concentrate in haemophilia A.
    Hazendonk HC; van Moort I; Fijnvandraat K; Kruip MJ; Laros-van Gorkom BA; van der Meer FJ; Meijer K; Peters M; Schutgens RE; Zwaan CM; Driessens MH; Polinder S; Leebeek FW; Mathôt RA; Cnossen MH
    Thromb Haemost; 2015 Aug; 114(3):639-44. PubMed ID: 26062822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Novel, Enriched Population Pharmacokinetic Model for Recombinant Factor VIII-Fc Fusion Protein Concentrate in Hemophilia A Patients.
    Bukkems LH; Heijdra JM; Mathias M; Collins PW; Hay CRM; Tait RC; Mangles S; Myers B; Evans G; Bailiff B; Curry N; Payne J; Austin S; Goedhart TMHJ; Leebeek FWG; Meijer K; Fijnvandraat K; Chowdary P; Mathôt RAA; Cnossen MH;
    Thromb Haemost; 2020 May; 120(5):747-757. PubMed ID: 32369846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII.
    Hermans C; Mahlangu J; Booth J; Schütz H; Santagostino E; Young G; Lee HY; Steinitz-Trost KN; Blanchette V; Berntorp E
    Haemophilia; 2018 May; 24(3):376-384. PubMed ID: 29732708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Importance of pharmacokinetics in the management of hemophilia.
    Barnes C
    Pediatr Blood Cancer; 2013; 60 Suppl 1():S27-9. PubMed ID: 23109436
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of moderate-intensity physical exercise on pharmacokinetics of factor VIII and von Willebrand factor in young adults with severe haemophilia A: a pilot study.
    Zourikian N; Merlen C; Bonnefoy A; St-Louis J; Rivard GE
    Haemophilia; 2016 May; 22(3):e177-83. PubMed ID: 26988074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A.
    McEneny-King A; Iorio A; Foster G; Edginton AN
    Expert Opin Drug Metab Toxicol; 2016 Nov; 12(11):1313-1321. PubMed ID: 27539370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population Pharmacokinetic Analysis of Recombinant Factor VIII Fc Fusion Protein in Subjects With Severe Hemophilia A: Expanded to Include Pediatric Subjects.
    Katragadda S; Neelakantan S; Diao L; Wong N
    J Clin Pharmacol; 2021 Jul; 61(7):889-900. PubMed ID: 33719084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII.
    Preijers T; van Moort I; Fijnvandraat K; Leebeek FWG; Cnossen MH; Mathôt RAA;
    Thromb Haemost; 2018 Mar; 118(3):514-525. PubMed ID: 29534249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PK-guided personalized prophylaxis with Nuwiq
    Lissitchkov T; Rusen L; Georgiev P; Windyga J; Klamroth R; Gercheva L; Nemes L; Tiede A; Bichler J; Knaub S; Belyanskaya L; Walter O; Pasi KJ
    Haemophilia; 2017 Sep; 23(5):697-704. PubMed ID: 28452151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Individualized Preventive Treatment of Patients with Severe Hemophilia A Guided by Multiple Clinical Parameters and Pharmacokinetics.
    Wang Y; Yang Q; Zheng L; Wang X; Jiang W; Lu L; Yan L; Zhang M; Chen L
    Acta Haematol; 2022; 145(4):354-361. PubMed ID: 34879368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients.
    Abrantes JA; Solms A; Garmann D; Nielsen EI; Jönsson S; Karlsson MO
    Haematologica; 2020 May; 105(5):1443-1453. PubMed ID: 31371418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response to Gringeri et al.: 'Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis--new insight provided by pharmacokinetic modelling'.
    Shapiro AD; Li S
    Haemophilia; 2015 Nov; 21(6):e489-92. PubMed ID: 26173031
    [No Abstract]   [Full Text] [Related]  

  • 37. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight.
    Björkman S; Oh M; Spotts G; Schroth P; Fritsch S; Ewenstein BM; Casey K; Fischer K; Blanchette VS; Collins PW
    Blood; 2012 Jan; 119(2):612-8. PubMed ID: 22042695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting dose sparing benefit and bleeding risk of pharmacokinetic-based personalized prophylactic dosing of factor VIII products.
    Tegenge MA; Yang H; Forshee RA
    Haemophilia; 2017 Sep; 23(5):705-711. PubMed ID: 28543946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients.
    Fijnvandraat K; Berntorp E; ten Cate JW; Johnsson H; Peters M; Savidge G; Tengborn L; Spira J; Stahl C
    Thromb Haemost; 1997 Feb; 77(2):298-302. PubMed ID: 9157585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia a patients.
    Preijers T; Liesner R; Hazendonk HCAM; Chowdary P; Driessens MHE; Hart DP; Laros-van Gorkom BAP; van der Meer FJM; Meijer K; Fijnvandraat K; Leebeek FWG; Mathôt RAA; Cnossen MH;
    Br J Clin Pharmacol; 2021 Nov; 87(11):4408-4420. PubMed ID: 33884664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.